Are you Dr. Dickler?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
205 E 64th St
New York, NY 10021Phone+1 212-639-2000Fax+1 212-794-5847
Summary
- Dr. Maura Dickler, MD is an oncologist in New York, New York. She is currently licensed to practice medicine in New York, Illinois, and Illinois. She is an Associate Professor at Weill Cornell Medical College.
Education & Training
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1991
Certifications & Licensure
NY State Medical License 1995 - 2026
IL State Medical License 1991 - 1996- IL State Medical License 1991 - 1996
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 4 citationsAn Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.Sarat Chandarlapaty, Maura N Dickler, Jose Alejandro Perez Fidalgo, Rafael Villanueva-Vázquez, Jennifer Giltnane
Clinical Cancer Research. 2023-08-01 - 7 citationsGenome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimensJulia C F Quintanilha, Jin Wang, Alexander B. Sibley, Wei Xu, Osvaldo Espin-Garcia
International Journal of Cancer. 2022-01-15 - 5 citationsA clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapyMei Yin C. Polley, Maura N. Dickler, Jason P. Sinnwell, Kathleen S. Tenner, Juan de la Haba
Breast Cancer Research and Treatment. 2021-07-03
Press Mentions
NCCN Patient Advocacy Summit Emphasizes Treating Every Cancer Patient as an IndividualDecember 10th, 2020- Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly OncologyDecember 3rd, 2020
FDA ODAC Votes on Safety and Efficacy of Ramucirumab plus Erlotinib for EGFR+ NSCLCFebruary 27th, 2020- Join now to see all
